Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

s0122206

—

7b22b345-e672-5a40-aa41-3f9550a566f8

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • IL6_JAK_STAT3_SIGNALING+0.600
  • INTERFERON_ALPHA_RESPONSE+0.600
  • INTERFERON_GAMMA_RESPONSE+0.600
  • ALLOGRAFT_REJECTION+0.500
  • COMPLEMENT+0.500
  • INFLAMMATORY_RESPONSE+0.500
  • TNFA_SIGNALING_VIA_NFKB+0.500
  • ANGIOGENESIS+0.400
  • APICAL_SURFACE+0.400
  • APOPTOSIS+0.400

Top 10 suppressed

  • MYC_TARGETS_V2-0.500
  • MYC_TARGETS_V1-0.400
  • UNFOLDED_PROTEIN_RESPONSE-0.300
  • E2F_TARGETS-0.200
  • OXIDATIVE_PHOSPHORYLATION-0.200
  • ADIPOGENESIS-0.100
  • DNA_REPAIR-0.100
  • G2M_CHECKPOINT-0.100
  • PROTEIN_SECRETION-0.100
  • HEME_METABOLISM+0.000

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

6 twins match this tumor's tissue · 4 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MDT-AP-2869
medullo-epn-umap@date-based
MedMedulloblastoma0.934
2BS_769BDPDB
brain-umap@2
pilocytic astrocytoma—0.931
3SRR10900576
melanoma-umap@29
——0.927
4SRR5088929
melanoma-umap@29
——0.921
5SRR8518191
breast-umap@18
—D0.920
6C3L-02601
lung-landscapes@6
—cohortA10.918
7BS_S9929Z8B
brain-umap@2
Ganglioglioma—0.916
8BS_JH29M4KG
brain-umap@2
pilocytic astrocytoma—0.916
9TCGA-77-8131-01A-11R-2247-07
lung-landscapes@6
—cohortSQ10.915
1024d909f2-cdc8-4509-91d5-e18fffcf90eb
colon-landscapes@1
——0.914

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 37 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
IL6_JAK_STAT3_SIGNALING0.600Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.600Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.600Idelalisib— uncovered
ALLOGRAFT_REJECTION0.500Idelalisib— uncovered
COMPLEMENT0.500Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.500Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.500Inavolisib— uncovered
ANGIOGENESIS0.400Remibrutinib— uncovered
APICAL_SURFACE0.400Temsirolimus— uncovered
APOPTOSIS0.400Idelalisib— uncovered
COAGULATION0.400Binimetinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.400Inavolisib— uncovered
IL2_STAT5_SIGNALING0.400Idelalisib— uncovered
KRAS_SIGNALING_UP0.400Inavolisib— uncovered
APICAL_JUNCTION0.300Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.300Remibrutinib— uncovered
ESTROGEN_RESPONSE_LATE0.300Idelalisib— uncovered
HYPOXIA0.300Idelalisib— uncovered
MYOGENESIS0.300Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.300Inavolisib— uncovered